| Ronald John Raymond, MD | |
|
30 Prospect St, Suite 200, Ridgefield, CT 06877-4514 | |
| (203) 438-9621 | |
| (203) 438-4596 |
| Full Name | Ronald John Raymond |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 32 Years |
| Location | 30 Prospect St, Ridgefield, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720013949 | NPI | - | NPPES |
| 001339698 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 033969 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Danbury Hospital | Danbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northeast Medical Group Inc | 1254233836 | 1251 |
News Archive
Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Metastases that were 2 millimeters or less in diameter ("micrometastases") in axillary lymph nodes detected on examination of a single section of the lymph nodes were associated with poorer disease-free and overall survival in breast cancer patients, according to a new study published online February 26 in the Journal of the National Cancer Institute.
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
› Verified 3 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Metastases that were 2 millimeters or less in diameter ("micrometastases") in axillary lymph nodes detected on examination of a single section of the lymph nodes were associated with poorer disease-free and overall survival in breast cancer patients, according to a new study published online February 26 in the Journal of the National Cancer Institute.
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ronald John Raymond, MD 1305 Post Rd, Lower Level, Fairfield, CT 06824-6016 Ph: (203) 292-2000 | Ronald John Raymond, MD 30 Prospect St, Suite 200, Ridgefield, CT 06877-4514 Ph: (203) 438-9621 |
News Archive
Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.
D-Pharm Ltd announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).
Metastases that were 2 millimeters or less in diameter ("micrometastases") in axillary lymph nodes detected on examination of a single section of the lymph nodes were associated with poorer disease-free and overall survival in breast cancer patients, according to a new study published online February 26 in the Journal of the National Cancer Institute.
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
› Verified 3 days ago
Dr. Jonathan Mark Gordon, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 21 South St, Ridgefield, CT 06877 Phone: 203-438-6541 | |
Dr. Cristina Hangwa Hung, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 51 Pheasant Ln, Ridgefield, CT 06877 Phone: 917-755-6040 | |
David B Huang, MD, PHD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 900 Ridgebury Rd # G4, Ridgefield, CT 06877 Phone: 203-791-6650 | |
Saragur M Jyothi, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 580 Barrack Hill Rd, Ridgefield, CT 06877 Phone: 203-431-8836 | |
Dr. Jennifer Beth Rubin, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 21 South St, Ridgefield, CT 06877 Phone: 203-438-6541 | |
Robert L Ruxin, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect St, Suite 300, Ridgefield, CT 06877 Phone: 203-438-7339 | |
Dr. Frank A Delli Carpini, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 67 Nutmeg Rdg, Ridgefield, CT 06877 Phone: 203-948-0543 Fax: 203-739-0405 |